Peripheral retinal dysfunction in patients taking vigabatrin

Neurology

Volumn 61, Issue 12, 2003, Pages 1690-1694

  McDonagh, J ^a   Stephen, L J ^b   Dolan, F M ^a   Parks, S ^a   Dutton, G N ^a   Kelly, K ^b   Keating, D ^a   Sills, G J ^b   Brodie, M J ^b  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIGABATRIN;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; COLOR VISION; CONTROLLED STUDY; DRUG SAFETY; ELECTRORETINOGRAM; EPILEPSY; FEMALE; HUMAN; MALE; OPHTHALMOSCOPY; PERIMETRY; PRIORITY JOURNAL; VISUAL ACUITY; VISUAL FIELD DEFECT;

EID: 0347364667     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000098938.80082.25     Document Type: Article

References (26)

1. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996;334:1583-1590.
2. Hancock E, Osborne JP, Milner P. The treatment of West syndrome: a Cochrane review of the literature to December 2000. Brain Dev 2001;23:624-634.
3. Schechter PJ, Tranier Y, Jung MJ, et al. Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic BAGA and gamma-vinyl GABA, two irreversible GABA-T inhibitors. Eur J Pharmacol 1977;45:319-328.
4. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314:180-181.
5. Lawden MC, Eke T, Degg C, et al. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999;67:716-722.
6. Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 1999;53:2082-2087.
7. Manuchehri K, Goodman S, Sivitel L, et al. A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 2000;84:499-505.
8. Hardus P, Verduin WM, Postma G, et al. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 2000;41:581-587.
9. Harding GFA, Wild JM, Roberston KA, et al. Electro-oculography, electroretinography, visual evoked potentials and multifocal electroretinography in patients with vigabatrin-associated visual field constriction. Epilepsia 2000;41:1420-1431.
10. Malmgren K, Ben-Menachem E, Frisén L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 2001;42:609-615.
11. Daneshvar H, Racette L, Coupland SG, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999;106:1792-1798.
12. Wild JM, Martinez C, Reinshagen G, et al. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999;53:922-926.
13. Kälviäinen R, Nousiainen I, Mäntyjärvi M, et al. Vigabatrin, a gabaergic drug, causes concentric visual field defects. Neurology 1999;52:1201-1205.
14. Harding GF, Wild JM, Roberston KA, et al. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus visual field loss. Neurology 2000;55:347-352.
15. Sutter EE, Tran D. The field topography of ERG components in man-I. The photopic luminance response. Vision Res 1992;32:433-446.
16. Hood DC. Assessing retinal function with the multifocal technique. Prog Retina Eye Res 2000;19:607-646.
17. Keating D, Parks S, Evans AL. Developments in ocular electrophysiology. Curr Med Lit Ophthalmol 2001;11:85-91.
18. Parks S, Keating D. Wide field functional imaging of the retina. IEEE Med Appl Signal Proc 1999;107:91-96.
19. McDonagh J, Grierson DJ, Keating D, Parks S. The wide field multifocal ERG reveals a retinal defect caused by vigabatrin toxicity? A case report. Br J Ophthalmol 2001;85:110.
20. Ratnaraj N, Patsalos PN. A high performance liquid chromatography micromethod for the simultaneous determination of vigabatrin and gabapentin in serum. Ther Drug Monit 1998;20:430-434.
21. Marmor MF, Zrenner E. Standard for clinical electro-oculography. Doc Ophthalmol 1993;85:115-124.
22. Marmor MF, Zrenner E. Standard for clinical electroretinography (1999 update). Doc Ophthalmol 1998;97:143-156.
23. Arndt CF, Derambure P, Defoort-Dhellemmes S, et al. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999;52:1201-1205.
24. Toggweiler S, Wieser H. Concentric visual field constriction under vigabatrin therapy: extent depends on the duration of drug intake. Seizure 2001;10:420-423.
25. Committee for Proprietary Medicinal Products. Opinion following an article 12 referral. Vigabatrin. The European Agency for the Evaluation of Medicinal Products (CPMP)-report/1357/99.
26. Sills GJ, Patsalos PN, Butler E, Forrest G, Ratnaraj N, Brodie MJ. Visual field constriction. Accumulation of vigabatrin but not tiagabine in the retina. Neurology 2001;57:196-200.